ADVM Investors Have Opportunity to Join Adverum Biotechnologies, Inc. Fraud Investigation with the Schall Law Firm

Core Viewpoint - The Schall Law Firm is investigating Adverum Biotechnologies, Inc. for potential violations of securities laws related to misleading financial statements and disclosures [1][2]. Group 1: Investigation Details - The investigation centers on whether Adverum made false or misleading statements and failed to disclose critical information to investors [2]. - Adverum announced in an SEC filing on March 31, 2025, that certain previously issued financial statements should no longer be relied upon due to non-cash errors in accounting for tenant improvement allowances related to an operating lease in North Carolina [2]. - The company plans to restate its financial statements for the years ended December 31, 2022, and 2023, as well as unaudited quarterly financial information for 2023 and 2024 [2]. - Following this announcement, Adverum's shares dropped by over 12% on April 1, 2025 [2]. Group 2: Shareholder Rights - The Schall Law Firm encourages shareholders who suffered losses to participate in the investigation and offers free consultations regarding their rights [3]. - The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [3].